

3/ 65

the area under the survival curve.

Expected lifetime and years lost

- ERL (Expected Residual Lifetime): Area under the survival curve
- > YLL (Years of Life Lost) (to diabetes, say): $ERL_{pop} ERL_{DM}$
- difference between areas under survival curve for persons without DM and persons with DM
- ${\scriptstyle \blacktriangleright}$ \Rightarrow area between the survival curves
- ... but not all use this approach

Expected Lifetime (erl-intro)

Years of Life Lost

Years of Life Lost to Diabetes LEAD symposiun at EDEG, Dubrovnik, 6 May 2017

http://BendixCarstensen.com/Epi/Courses/EDEG2017

Wikipedia: PYLL

Potential Years of Life Lost

- Fix a threshold, T, (the population EL, or say 75)
- A person dead in age a < T contributes T a
- A person dead in age a > T contributes 0

 \ldots seems to assume that the expected age at death is ${\it T}$ regardless of attained age ?

Years of Life Lost (yll-intro)

9/ 65

10/ 65

8/65

WHO — Years of Life Lost

Rationale for use

Years of life are lost (YLL) take into account the age at which deaths occur by giving greater weight to deaths at younger age and lower weight to deaths at older age. The years of life lost (percentage of total) indicator measures the YLL due to a cause as a proportion of the total YLL lost in the population due to premature mortality.

Definition

YLL are calculated from the number of deaths multiplied by a standard life expectancy at the age at which death occurs. The standard life expectancy used for YLL at each age is the same for deaths in all regions of the world (\dots)

www.who.int/whosis/whostat2006YearsOfLifeLost.pdf

```
\Rightarrow a person dying in age a contributes ERL(a) > 0
```

Years of Life Lost (yll-intro)

Comparing men and women When a man dies age a, say, YLL is ERL_w(a) > 0 — the expected residual life time of a woman aged a. When a woman dies age a, say, YLL is ERL_m(a) > 0 — the expected residual life time of a man aged a. ... so each sex lose years relative to the other ! So maybe not a terribly useful measure. Yeas of Life Leet (y11-istre) The ad-hoc measures do not work

- anyone who dies before age 75 (PYLL)
- anyone who dies (WHO YLL)
- ... contribute a **positive** number to YLL
- ➤ ⇒ any subgroup of the population have positive years of life lost when compared to the general population!

11/65

12/65


- ... actually, compared to **any** population (ex: men vs. women)
- They only use the dead persons and ignore the living
- No shortcuts:
 - the YLL is a difference of expectations
 - use a statistical model (specify f(a), that is)
 - a statistical model for all persons
 - We will use diabetes in Denmark as an example
- ars of Life Lost (yll-intro)


YLL — the details

Years of Life Lost to Diabetes LEAD symposiun at EDEG, Dubrovnik, 6 May 2017

http://BendixCarstensen.com/Epi/Courses/EDEG2017

How the world looks






18/ 65

19/65

20/65

21/65



Comparing DM and well in the real world

The survival function $S_W(a)$ is the sum of:

$$P \{ \mathsf{Well} \}(a) = \exp\left(-\int_0^a \mu_W(u) + \lambda(u)\right) \, \mathrm{d}u$$

and

YLL — the de

$$\begin{split} \mathrm{P}\left\{\mathsf{DM}\right\}(a) &= \int_{0}^{a} \mathrm{P}\left\{\mathsf{survive to } s, \ \mathsf{DM} \ \mathsf{diagnosed at } s\right\} \\ &\quad \times \mathrm{P}\left\{\mathsf{survive with } \mathsf{DM} \ \mathsf{from } s \ \mathsf{to} \ a\right\} \ \mathrm{d}s \\ &= \int_{0}^{a} \lambda(s) \exp\left(-\int_{0}^{s} \mu_{W}(u) + \lambda(u) \ \mathrm{d}u\right) \\ &\quad \times \exp\left(-\int_{s}^{a} \mu_{D}(u) \ \mathrm{d}u\right) \ \mathrm{d}s \end{split}$$

Comparing DM and well in the real world

The **conditional** survival function given **Well at** A is the sum of

Note: This is **not** $S_W(a)/S_W(A)$ because we are not conditioning on being alive, but conditioning on being alive and well at age A


A brutal shortcut

 \ldots sooo hairy, so why don't we not just use the total population mortality, $\mu_{T},$ and instead compare:

$$S_T(a) = \exp\left(-\int_0^a \mu_T(u) \,\mathrm{d}u\right), \qquad S_D(a) = \exp\left(-\int_0^a \mu_D(u) \,\mathrm{d}u\right)$$

- There is no simple relation between S_T and the correctly computed S_W so there is no guarantee that it will be useful, nor the direction of bias
- The comparison will be between a random person with diabetes and a random person (with or without diabetes)
- Empirical question whether this is a reasonable approximation

YLL — the details (DK-ex)



Danish diabetes data

luction (exc-intro)

24/65


25/65


_					-										
	> d	ata	(y(Ej DMep Mepi	i)										
	[1]	40	00		8										
	> h	ead	(DMep.	i))									
	1 2 3 4 5 6	F M F M	0 0 1 1 2 2	1996 1996 1996 1996 1996 1996	1 9 4 7 7 2	19 23 19 7 8	35453.65 33094.86 36450.73 34789.99 35328.92 33673.43	0 0 0 0 0 0	0 3 4 7 12 8	.4757 .8767 .9199 .2484 .4743 .0951	967 179 600 326 403				
	> w	15	<-				[epi, sex= [w15\$A),]	="F" 8	& F	==201	5)				
	[1]	10	0	8											
Practic	als intr	oduct	ion	(exc-in	tro)										28/65


27/65

Danish diabetes data


+++>	Sw < Sd <	<- transfor - surv1(1 - surv1(1 d(Sw, Sd)	i m m , w15\$mW, , w15\$mD,	W = D = p T = A=65	omax(0,D.D. (D.nD+D.D.)	X / Y.nD, M / Y.DM,n	<pre># no DM morta # DM inciden a.rm=TRUE), # .DM)) # total</pre>	ce DM mortality
	age	AO	A65	age	AO	A65		
63		0.9418470	1.0000000	62	0.8169978	1.0000000		
64	63	0.9357472	1.0000000	63	0.7989680	1.0000000		
65	64	0.9297246	1.0000000	64	0.7853495	1.0000000		
66	65	0.9226514	1.0000000	65	0.7721934	1.0000000		
67	66	0.9149180	0.9916183	66	0.7547042	0.9773513		
68	67	0.9070037	0.9830406	67	0.7381123	0.9558646		
69	68	0.8990846	0.9744576	68	0.7214464	0.9342820		
70	69	0.8909150	0.9656030	69	0.7061645	0.9144918		
71	70	0.8803810	0.9541860	70	0.6918332	0.8959326		
72	71	0.8700207	0.9429572	71	0.6689975	0.8663601		
Practicals in	troducti	on (exc-intro)						29/ 65







- Compute YLL for all combinations of:
 - sex
 - ▶ conditioning ages 30–90
 - ▶ dates 1996-2016
 - methods: Susceptible / Immune / Total approx.
- Show for select combinations



Years of Life Lost to diabetes: Conclusion

- ▶ Use a model
- ▶ for **all** your rates
- use your probability theory
- credible models for rates requires: smooth parametric function of age and calendar time
- continuous time formulation simplifies concepts and computing
- using non-DM mortality (immunity assumption) overestimates YLL
- If you cannot do it correctly for want of data: compare with the **total** population mortality
- but it may be misleading too...

Sojourn times Years of Life Lost to Diabetes LEAD symposiun at EDEG, Dubrovnik, 6 May 2017 http://BendixCarstensen.com/Epi/Courses/EDEG2017

And now for something slightly different

- YLL is really difference in the time spent in the state "Alive"
- There might be more states than just "Alive" and "Dead" ► For example how much time is spent free of a particuar complication?
- ▶ Example here: Steno 2 study, and time spent with CVD.



46/65

48/65

Diabetologia DOI 10.1007/s00125-016-4065-6 ARTICLE

Years of life gained by multifactorial intervention in patients with type 2 diabetes mellitus and microalbuminuria: 21 years follow-up on the Steno-2 randomised trial

49/65

() Cro

pharmacological approaches. After 7.8 years the study contin


ued as an observational follow-up with all patients receiving


Peter Gæde^{1,2} · Jens Oellgaard^{1,2,3} · Bendix Carstensen³ · Peter Rossing^{3,4,5} · Henrik Lund-Andersen^{3,5,6} · Hans-Henrik Parving^{5,7} · Oluf Pedersen⁸

Received: 7 April 2016 / Accepted: 1 July 2016 © The Author(s) 2016. This article is published with open access at Springerlink.com

Abstract

Aims/hypothesis The aim of this work was to study the poten-





Models

- As we did for mortality and incidence rates:
- Fit a model for each of the transitions
- We used proportional hazards for:
 - CVD-rates
 - mortality rates
- rates depending on age, sex, randomization group and CVD status

	CVD event	Mortality
HR, Int. vs. Conv.	0.55 (0.39;0.77)	0.83 (0.54; 1.30)
H ₀ : PH btw. CVD groups	p=0.261	p=0.438
H_0 : $HR = 1$	p=0.001	p=0.425
HR vs. 0 CVD events:		
0 (ref.)	1.00	1.00
1	2.43 (1.67;3.52)	3.08 (1.82; 5.19)
2	3.48 (2.15;5.64)	4.42 (2.36; 8.29)
3+	. ,	7.76 (4.11;14.65)

Practical modeling of rates

- Cut the follow-up time for each person by state
- Split the follow-up time in 1-month intervals
- Poisson model with smooth effect of time since randomization, sex and age at entry:
 - HR estimates
 - Estimates of baseline hazard
 - Hazard for any set of covariates
- Allows calcualtion of expected sojourn time in any state
- analytically this is totally intractable...


Estimating sojourn times


- Use simulation of the state occupancy probabilities:
- Lexis machinery in the Epi package for multistate representation
- splitLexis to subdivide follow-up for analysis
- simLexis for simulation to derive probabilities and sojourn times
- simulates a cohort through the model, so probabilities are just empirical fractions

53/ 65

54/65

55/65





tween groups (HK 0.83 [95% CI 0.54, 1.30], p=0.43). In between groups (ITR UAS 195% CI 0.54, 1.30, *p*=0.45). This the reduced motifiely was primarily due to reduced risk of CVD. The patients in the intensive group experienced a total of 90 cardiovascular events vs 195 events in the conventional group. Nineteen intensive-group patients (24%) vs 43 conventional-group patients (24%) experienced more than one cardiovascular event. No significant between-group difference in the distribution of specific cardiovascular first-event types was observed (Table 2 and Fig. 4).

56/65

58/65

59/65

Microvascular complications Hazard rates of progra Microvascular complications Hazard rates of progression rates in microvascular complications compared with baseline status are shown Fig. 3. Sensitivity analyses showed a negli-gible effect of the random dates imputation. Progression of retinopathy was decreased by 33% in the intensive-thempy group (Fig. 5). Blindness in at least one eye was reduced in the intensive-thempy group with an HR of 0.47 (95% cf 10.23, 0.98, p= 0.044). Autonomic neuropathy was decreased by 41% in the intensive-thempy group (Fig. 5). We observed no difference between groups in the progression of peripheral neuropathy (Fig. 5). Progression to diabetic ne-phropathy (macroalbuminaria) was reduced by 48% in the intensive-therapy group (Fig. 5). Ten patients in the intensive-therapy group yes five patients in the intensive-therapy group progressed to end-stage renal disease (p=0.061).

Discussion

Expected lifetime and YLL (well, gained)

Expected lifetime (years) in the Steno 2 cohort during the first 20 years after baseline by treatment group and CVD status.

State	Intensive	Conventional	IntConv.		
Alive	15.6	14.1	1.5		
No CVD	12.7	10.0	2.6		
Any CVD	3.0	4.1	-1.1		

- Simulate a cohort with same covariate dist'n as the study
- Population averaged years gained alive / CVD-free
- Refer only to the Steno 2 trial population Not generalizable
- ... but we have a model

